Development of new prolactin analogs acting as pure prolactin receptor antagonists

Pituitary

Volumn 6, Issue 2, 2003, Pages 89-95

  Goffin, Vincent ^a   Bernichtein, Sophie ^a   Kayser, Christine ^a   Kelly, Paul A ^a  

^a INSERM   (France)

Author keywords

Antagonist; G129R hPRL; Mammary gland neoplasia; Prolactin; Prolactin receptor; Prostate hyperplasia

Indexed keywords

ARGININE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE; G 120R HGH; G 129R HPRL; GLYCINE; HORMONE RECEPTOR BLOCKING AGENT; LIGAND; PEGVISOMANT; PROLACTIN; PROLACTIN DERIVATIVE; PROLACTIN RECEPTOR; S 179D HPRL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; AUTOCRINE EFFECT; BINDING COMPETITION; BIOASSAY; DOSE RESPONSE; DRUG ACTIVITY; DRUG INDICATION; DRUG RESEARCH; DRUG USE; EVIDENCE BASED MEDICINE; EXPERIMENTAL NEOPLASM; HORMONE ACTION; HORMONE INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TARGET ORGAN; TRANSGENIC MOUSE; TREATMENT FAILURE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROLACTIN; RECEPTORS, PROLACTIN;

EID: 0346777277     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PITU.0000004799.41035.9f     Document Type: Review

References (52)

1. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27.
2. Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000;19:1072-1076.
3. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 2000;19:1077-1084.
4. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997;100:2744-2751.
5. Wang DY, De Stavola BL, Bulbrook RD, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992;21:214-221.
6. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000;9:575-579.
7. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85.
8. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-634.
9. Touraine P, Martini JF, Zafrani B, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998;83:667-674.
10. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997;138:5555-5560.
11. Mertani HC, Garcia-Caballero T, Lambert A, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 1998;79:202-211.
12. Brockman JL, Schroeder MD, Schuler LA. PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 2002;16:774-784.
13. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-1021.
14. Brisken C, Ayyannan A, Nguyen C, et al. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002;3:877-887.
15. Sciacca L, Costantino A, Pandini G, et al. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene 1999;18:2471-2479.
16. Anderson E, Ferguson JE, Morten H, Shalek SM, Robinson EL, Howell A. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. Eur J Cancer 1993;29A:209-217.
17. Bonneterre J, Mauriac L, Weber B, et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: Results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol 1988;24:1851-1853.
18. Manni A, Boucher AE, Demers LM, et al. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 1989;14:289-298.
19. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: Distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639-669.
20. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55:2591-2595.
21. Clevenger CV, Chang WP, Ngo W, Pasha TM, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Am J Pathol 1995;146:695-705.
22. Mershon J, Sall W, Mitchner N, Ben-Jonathan N. Prolactin is a local growth factor in rat mammary tumors. Endocrinology 1995;136:3619-3623.
23. Clevenger CV, Plank TL. Prolactin as an autocrine/paracrine factor in breast cancer. J Mammary Gland Biol Neopl 1997;2:59-68.
24. Llovera M, Touraine P, Kelly PA, Goffin V. Involvement of prolactin in breast cancer: Redefining the molecular targets. Exp Gerontol 2000;35:41-51.
25. Ben Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002;13:245-250.
26. Kindblom J, Dillner K, Sahlin L, et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 2003;144:2269-2278.
27. Kindblom J, Dillner K, Ling C, Tornell J, Wennbo H. Progressive prostate hyperplasia, in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 2002;53:24-33.
28. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene 2003;22(30):4664-4674.
29. Baudhuin A, Manfroid I, Van De WC, Martial JA, Muller M. Transcription of the human prolactin gene in mammary cells. Ann NY Acad Sci 2002;973:454-458.
30. Goffin V, Kelly PA. The prolactin/growth hormone receptor family: Structure/function relationships. J Mammary Gland Biol Neopl 1997;2:7-17.
31. Goffin V, Shiverick KT, Kelly PA, Martial JA. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev 1996;17:385-410.
32. Kinet S, Bernichtein S, Llovera M, Kelly PA, Martial JA, Goffin V. Molecular basis of the interaction between human prolactin and its membrane receptor: A ten year study. Recent Res Devel Endocrinol 2001;2:1-24.
33. Wells JA. Binding in the growth hormone receptor complex. Proc Natl Acad Sci USA 1996;93:1-6.
34. Frank SJ. Minireview: Receptor dimerization in GH and erythropoietin action-It takes two to tango, but how? Endocrinology 2002;143:2-10.
35. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992;256:1677-1680.
36. Goffin V, Struman I, Mainfroid V, Kinet S, Martial JA. Evidence for a second receptor binding site on human prolactin. J Biol Chem 1994;269:32598-32606.
37. Goffin V, Kinet S, Ferrag F, Binart N, Martial JA, Kelly PA. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 1996;271:16573-16579.
38. Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem 1995;270:13133-13137.
39. Llovera M, Pichard C, Bernichtein S, et al. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 2000;19:4695-4705.
40. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 1999;5:3583-3593.
41. Beck MT, Peirce SK, Chen WY. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 2002;21:5047-5055.
42. Cataldo L, Chen NY, Yuan Q, et al. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int J Oncol 2000;17:1179-1185.
43. Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen Wy. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Int J Oncol 2002;20:813-818.
44. Kinet S, Bernichtein S, Kelly PA, Martial JA, Goffin V. Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites. J Biol Chem 1999;274:26033-26043.
45. Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V. New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 2003;20:177-190.
46. Ormandy CJ, Camus A, Barra J, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11:167-178.
47. Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY, Walker AM. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 1998;139:609-616.
48. Bernichtein S, Kinet S, Jeay S, et al. S179D-hPRL, a pseudophosphorylated human prolactin analog, is an agonist and not an antagonist. Endocrinology 2001;142:3950-3963.
49. Bernichtein S, Jomain J-B, Kelly PA, Goffin V. The N-terminus of human prolactin modulates its biological properties. Mol Cel Endocrinol 2003, in press.
50. Bernichtein S, Kayser C, Dillner K, Kopchick JJ, Isaksson OGP, Norstedt G, Martial JA, Kelly PA, Goffin V. Development of pure prolactin antagonists. J Biol Chem 2003;278(38):35988-35999.
51. Goffin V, Bernichtein S, Carrière O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999;140:3853-3856.
52. Kaulsay KK, Zhu T, Bennett W, Lee K, Lobie PE. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 2001;142:767-777.